跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2016-000499-83-DE
EUCTR2016-000499-83-DE进行中（未招募）1 期

A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH. - PoM in target population

Boehringer Ingelheim Pharma GmbH & Co. KG0 个研究点目标入组 108 人开始时间: 2017年4月28日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
108
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Clinical evidence of NASH defined as
  • •a. histological evidence of NASH (no more than 3 years prior to
  • •b. clinical imaging results suggestive of NASH (no more than 3 years
  • •screening OR within the screening phase, imaging procedures performed
  • •as per local standard)
  • •i. evidence of hepatic steatosis >5% measured by the MRI-PDFF or
  • •assessed as
  • •steatosis (raised echogenicity of the liver parenchyma) by ultrasound
  • •ii. evidence of liver fibrosis defined as mean stiffness > 3.64 kPa as
  • •measured by
  • •the MRE protocol or mean stiffness > 7.2 kPa as measured by ultrasound
  • •transient elastography (Fibroscan®)
  • •2. Increased ALT defined as
  • •a. ALT >1.5 ULN at screening and ALT >1.25 ULN in a local lab within 1
  • •week to 3 months prior screening
  • •b. Historic ALT > 1.25 ULN more than 3 months prior to screening and
  • •two consecutive ALT > 1.5xULN must be confirmed at least 1 week apart
  • •within the screening period
  • •3. Age = 18 and =75 years at screening
  • •4. BMI =25kg/m2 and <45kg/m2 at screening
  • •5. Stable body weight defined as less than 5% change in body weight in
  • •the 3 months
  • •prior to screening while being treated with the standard of care and not
  • •treated with
  • •anti-obesity medication at screening.
  • •6. Treatment with Antidiabetic concomitant medication including any
  • •insulin regimen needs to be stable for 3 months, and treatment with vitamin E needs to be stable for 6 months prior to informed consent and expected to be stable throughout the trial. All other concomitant medication has to be stable for at least 4 weeks prior screening.
  • •Concomitant medications taken to treat acute conditions (e.g. headache,
  • •sinusitis) for a short period (< 7 days) are permissible, if not otherwise prohibited.
  • •For restricted medications please refer to section 4.2.2.1.
  • •7. For female patients: Women of childbearing potential* can be
  • •randomized after a negative pregnancy test and under adequate contraception with two methods, of which at least one is highly effective, during the trial.
  • •* A woman is considered of childbearing potential (WOCBP), i.e. fertile,
  • •following menarche and until becoming post-menopausal unless permanently
  • •Permanent sterilisation methods include hysterectomy, bilateral
  • •salpingectomy and
  • •bilateral oophorectomy. Tubal ligation is NOT a method of permanent
  • •sterilisation.
  • •A postmenopausal state is defined as no menses for 12 months without
  • •an alternative
  • •medical cause.
  • •8. Signed and dated written informed consent in accordance with GCP
  • •legislation prior to admission to the trial.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 88
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 20

排除标准

  • •1. Current or history of significant alcohol consumption (defined as intake of >210g/week in males and >140g/week in females on average over a consecutive period of more than 3 months) or inability to reliably quantify alcohol consumption based on investigator judgement.
  • •2. Prior participation in an interventional NASH trial 6 months before baseline or 5 times halflife of the investigational drug, whichever is longer.
  • •3. Prior or planned bariatric surgery during study conduct, except gastric-band surgery more than 2 years prior to screening (including adjustments) with a stable body weight within the last 12 months.
  • •4. Use of drugs historically associated with liver injury, hepatic steatosis or steatohepatitis in the 4 weeks prior to screening; please refer to section 4.2.2.
  • •5. History of liver cirrhosis (fibrosis stage 4), or hepatic decompensation (e.g. ascites, hepatic encephalopathy, variceal bleeding, etc.) or history of other forms of chronic liver disease (for example Hepatitis B, Hepatitis C, autoimmune liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilsons disease, hemochromatosis, A1At deficiency, history of liver transplantation).
  • •6. Active known chronic or relevant acute infections, such as HIV (Human Immunodeficiency Virus), \viral hepatitis, or tuberculosis. QuantiFERON® TB test and HBs Ag test will be performed during screening. Patients with a positive test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active infection.
  • •7. Solid liver lesions other than haemangiomas. a. Suspicion or diagnosis or history of hepatocellular carcinoma (HCC)
  • •8. eGFR <60ml/min/1.73m2 at screening (CKD-EPI formula).
  • •9. ALT >5.0 ULN at screening.
  • •10. Platelet count < 150.000/µL
  • •11. Bilirubin level > ULN (except for known Gilbert´s disease with a conjugated bilirubin of < 0.3 mg/dL))
  • •12. Uncontrolled diabetes defined as an HbA1c =9.5% in the 3 months prior to or at screening.
  • •13. Diagnosis of a serious or unstable disease including hepatic (other than NASH), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic , psychiatric, immunologic, or hematologic disease and other conditions that, in the clinical judgment of the investigator, are likely to interfere with the analyses of safety and efficacy in this study. Patients with an expected life expectancy of less than 2 years are also excluded.
  • •14. Major surgery (major according to the investigator’s assessment) performed within 12 weeks prior to randomisation or planned during study conduct, e.g. hip replacement.
  • •15. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  • •16. Patients who must or wish to continue the intake of restricted medications (see section 4.2.2.1) or any drug considered likely to interfere with the safe conduct of the trial
  • •17. Previous randomisation in this trial.
  • •18. Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational treatment(s).
  • •19. Chronic drug abuse or any condition that, in the investigator’s opinion, makes them an unreliable study subject or unlikely to complete the t

研究者

相似试验

已完成
2 期
A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.
NL-OMON47669Boehringer Ingelheim2
已完成
2 期
A multi-centre, double-blind, parallel-group, randomized controlled study to investigate the efficacy, safety and tolerability of orally administred BI 409306 during a 12-week treatment period compared to placebo in patients with Alzheimer's disease.prodromal Alzheimer Disease/Alzheimer Disease10029305
NL-OMON42045Boehringer Ingelheim12
进行中（未招募）
1 期
Different doses of BI 1467335 compared to placebo in patients with clinical evidence of NASHon-alcoholic steatohepatitisMedDRA version: 20.0 Level: PT Classification code 10076331 Term: Steatohepatitis System Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2016-000499-83-IEBoehringer Ingelheim Limited108
进行中（未招募）
1 期
BI 425809 in patients with cognitive impairment due to Alzheimer's Disease.Cognitive impairment due to Alzheimer's Disease Patients with diagnosis of mild-to moderate Alzheimer’s dementia according to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders
EUCTR2015-005438-24-GBBoehringer Ingelheim Limited950
进行中（未招募）
1 期
Different doses of BI 1467335 compared to placebo in patients with clinical evidence of NASHon-alcoholic steatohepatitisMedDRA version: 20.0 Level: PT Classification code 10076331 Term: Steatohepatitis System Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2016-000499-83-BESCS Boehringer Ingelheim Comm. V108
Different doses of BI 1467335 compared to placebo in... | 临床试验